Survival benefit of ICD implantation for primary prevention in dilated cardiomyopathy

Document Type : original articles

Authors

1 Yazd Cardiovascular Research Center, Non-communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Department of Radiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Abstract

Objectives: Dilated cardiomyopathy (DCM) represents a significant cause of heart failure unrelated to ischemic heart disease, posing a high risk of sudden cardiac death (SCD) due to low left ventricular ejection fraction (LVEF). This study evaluates the survival benefits of implantable cardiac defibrillators (ICDs) for primary prevention in DCM patients.

Methods: We enrolled 52 symptomatic non-ischemic cardiomyopathy patients (LVEF ≤ 35%, NYHA class II-III) eligible for ICD implantation in Afshar Hospital, Yazd, Iran, from 2014 to 2015. Exclusion criteria included those with ischemic indications or requiring cardiac resynchronization therapy. We divided patients into ICD recipients and those on a waiting list, collected the baseline data (age, functional class, LVEF), then followed up with patients to assess mortality rates.

Results: Among 45 patients, 64.5% received ICDs while 35.5% were on the waiting list. The mean age was 57±13 years, predominantly male (67.3%). The ICD group had a significantly lower mortality rate (17.3%) than the waiting list group (42.7%, p = 0.54). Although age and functional class did not significantly predict outcomes, lower LVEF was a crucial factor for long-term survival. Despite some studies suggesting no survival benefit in non-ischemic heart failure, our findings highlight the efficacy of ICDs in reducing mortality among DCM patients.
 
Conclusions: ICD implantation in DCM patients substantially reduces all-cause mortality compared to those awaiting the procedure, underscoring the importance of timely ICD deployment for primary prevention in this population.

References

1.Wang K, Xu X, Qi Y, et al. Comparison of the benefit of primary prevention implantable cardioverter- defibrillator therapy in ischemic versus nonischemic dilated cardiomyopathy. Authorea. 2020.
2.Halliday BP, Cleland JG, Goldberger JJ, et al. Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future. Circulation. 2017; 136(2):215-231.
3.Sun WP, Li CL, Guo JC, et al. Long-term efficacy of implantable cardiac resynchronization therapy plus defibrillator for primary prevention of sudden cardiac death in patients with mild heart failure: an updated meta-analysis. Heart Fail Rev. 2016; 21(4):447-53.
4.Pezawas T, Grimm M, Ristl R, et al. Primary preventive cardioverter‐defibrillator implantation (Pro‐ ICD) in patients awaiting heart transplantation.A prospective, randomized, controlled 12‐year follow‐up study. Transpl Int. 2015; 28(1):34-41.
5.Clementy N, Challal F, Marijon E, et al. Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study. Heart Rhythm. 2017; 14(2):211-217.
6.Algalarrondo V, Perault R, Bories MC, et al. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation. Arch Cardiovasc Dis. 2018; 111(12):758-765.
7.Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000; 21(24): 2071-8.
8.Ursaru AM, Petris AO, Costache II, et al. Comparable Efficacy in Ischemic and Non-Ischemic ICD Recipients for the Primary Prevention of Sudden Cardiac Death. Biomedicines. 2021; 9(11):1595.
9.Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016; 375(13):1221-30.Ponikowski P, Voors AA, Anker SD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-200.
10.Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27):2129-2200.
11.Kołodziejczak M, Andreotti F, Kowalewski M, et al. Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: a systematic review and meta- analysis.  Ann Intern Med. 2017; 167(2):103-111.
12.Pathak RK, Sanders P, Deo R. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy. Eur Heart J. 2018;39(31):2859-2866.
13.Da Rosa MR, Sapp JL, Howlett JG, et al. Implantable cardioverter-defibrillator implantation as a bridge to cardiac transplantation. J Heart Lung Transplant.2007; 26(12):1336-9.
14.Santangeli P, Di Biase L, Russo AD, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter- defibrillators. Ann Intern Med. 2010;153(9): 592-9.
15.Golwala H, Bajaj NS, Arora G, et al. Implantable cardioverter- defibrillator for nonischemic cardiomyopathy: an updated meta-analysis. Circulation.2017;135(2): 201-203.
16.Dagres N, Hindricks G. Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death? Eur Heart J. 2013;34(26):1964-71.
17.Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: a meta-analysis. JAMA cardiol. 2017;2(6):685-688.
Cardiovascular Biomedicine
Volume 4, Issue 1
August 2024
Pages 26-30

Files

History

  • Receive Date: 06 June 2024
  • Revise Date: 04 August 2024
  • Accept Date: 07 August 2024

Share

How to cite

Statistics